The Food and Drug Administration aims to ensure hackers can’t remotely access or control medical devices, and it’s asking the private sector to do more to protect those devices.
Earlier this month, FDA issued draft guidance directing manufacturers to conduct “postmarket” evaluation of their devices, ensuring device security vulnerabilities won’t affect clinical performance.
Alexandria is the largest and leading urban office REIT uniquely focused on collaborative science and technology campuses in AAA innovation cluster locations. The firm currently has more than 19 million rentable square feet of operating properties, as well as development and redevelopment projects under construction, with another 11.6 million square feet in near-term and future ground-up development projects. Alexandria was the first to pioneer this niche under CEO Joel Marcus’ vision when he founded the company in 1994. Since then, the firm has established a dominant market presence across the industry in locations such as Greater Boston/Cambridge, San Francisco, New York City, San Diego, Seattle, Maryland and Research Triangle Park.
Stephanie Fertig and Kory Hallett from the National Institutes of Health (NIH) will give an overview of SBIR and STTR Small Business programs at the NIH.
The talk will include:
At the end of their presentation, the speakers will respond to questions from the audience.
If you want to find ways to expand your biomedical startup using NIH funding, you won’t want to miss this webinar!
T. Rowe Price sunk gobs of money into companies such as Cloudera, Dropbox, Apptio and Evernote in recent years, oftentimes at lofty valuations.
Now, the giant mutual fund manager is resetting some of those bets. According to a report in The Information (subscription required), T. Rowe Price has marked down its stakes in a number of companies.
British pharmaceutical firm GlaxoSmithKline is reportedly discussing terms of a medtech joint venture with US chipmaker Qualcomm.
Talks between the two companies to form a partnership to develop medical technology are “preliminary and nothing has been decided”, reports Bloomberg, citing unnamed sources privy to the information. The Financial Times says the deal could be worth as much as $1 billion, and GSK reportedly has hired lawyers to help negotiate the terms of the joint venture with Qualcomm. If confirmed, FT expects the companies “to pool financial and human resources in a joint effort to develop new technology for use in the pharmaceuticals industry.”
May 8 – 11, 2016 – Grand Hyatt Washington DC in Washington, DC
Health Datapalooza is a national conference focused on liberating health data, and bringing together the companies, startups, academics, government agencies, and individuals with the newest and most innovative and effective uses of health data to improve patient outcomes.
Roche will partner with the Lead Discovery Center (LDC) to identify and advance drug discovery projects intended to address diseases of unmet medical need across several areas. The value of the collaboration and the diseases to be addressed were not disclosed by the LDC, which announced the partnership today.
WIB has collaborated with BioProcess International (BPI), the biopharmaceutical industry´s leading scientific publication, to publish a four-part WIB/BPI special report series in 2016. The mission of this special report series is to provide a unique and interactive platform to reach and educate women (and all professionals) working in the life sciences with insight, mentorship, and leadership support through all stages of career development. Each edition of the WIB/BPI special report series will focus on critical issues all biotechnology professionals need to know, understand and manage in order to climb the corporate ladder and achieve the highest levels of leadership.
This is an opportunity to hear from NIST’s leadership about their important mission, a multi-million dollar laboratory expansion, cybersecurity implementation, and vendor opportunities in construction and IT.
Participants will also have the opportunity to meet representatives from many of the NIST Operating Units and contracting officials at exhibitor tables, speak one-on-one with the panelists, and network with fellow government contractors.
More innovation will be the determining factor in achieving greater progress. Countries’ economic and trade policies can either help or hurt global innovation. For example, policies such as robust investment in and tax incentives for research and education support global innovation. In contrast, policies such as export subsidies or forced localization harm global innovation.
